Mike Kratky Analyst PerformanceSenior Managing Director, Medical Devices and Technology at Leerink PartnersMike Kratky is a stock analyst at Leerink Partners in the medical sector, covering 14 publicly traded companies. Over the past year, Mike Kratky has issued 20 stock ratings, including buy and hold recommendations. While full access to Mike Kratky's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mike Kratky's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings22 Last 1 YearsBuy Recommendations72.73% 16 Buy RatingsCompanies Covered14 Unique Companies Ratings Distribution22RatingsDistribution of strong buy, buy, hold, and sell ratings by Mike Kratky.RatingPercentageCount Strong Buy0.0%0 ratings Buy72.7%16 ratings Hold27.3%6 ratings Sell0.0%0 ratingsOut of 22 total stock ratings issued by Mike Kratky at Leerink Partners, the majority (72.7%) have been Buy recommendations, followed by 27.3% Hold.Best & Worst CallsBest Call000.0%BBNXFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ57.1% of companies on NASDAQ8 companiesNYSE42.9% of companies on NYSE6 companiesMike Kratky, an analyst at Leerink Partners, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies100.0%Mike Kratky of Leerink Partners specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED INSTRUMENTS6 companies42.9%MED PRODUCTS5 companies35.7%MEDICAL INFO SYS2 companies14.3%MED - BIOMED/GENE1 company7.1% About Mike KratkyMike Kratky, CFA is as a Senior Research Analyst at Leerink Partners, specializing in the coverage of Medical Devices and Technology. Mike initially joined the Firm in 2018 as an Associate focused on the immunology and inflammation space. Recognized for his exceptional contributions, he was promoted to Vice President before leaving the Firm in March 2020. Subsequently, Mike gained valuable experience during his one-year tenure at Verition Fund Management and later rejoined Leerink Partners in March 2021. Prior to his time at Leerink Partners, he held various roles at B. Riley FBR, Nasdaq, and MKM Partners. Mike earned his B.A. in Economics from Colgate University and holds the Chartered Financial Analyst designation.Follow on LinkedIn Mike Kratky's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsISRGIntuitive Surgical4/22/2026Lower Price Target$481.31$573.00Outperform$0.0000.00% ROIBBNXBeta Bionics4/22/2026Lower Price Target$11.48$24.00Outperform$0.0000.00% ROISYKStryker4/13/2026Initiated Coverage$339.32$410.00Outperform$0.0000.00% ROIZBHZimmer Biomet4/13/2026Initiated Coverage$93.14$101.00Hold$0.0000.00% ROIVCELVericel3/10/2026Reiterated Rating$33.40$46.00Outperform$0.0000.00% ROIMDTMedtronic3/10/2026Reiterated Rating$90.21$119.00Outperform$0.0000.00% ROIPRCTPROCEPT BioRobotics2/26/2026Lower Price Target$23.52$30.00Outperform$0.0000.00% ROIPODDInsulet2/19/2026Lower Price Target$258.07$360.00Outperform$0.0000.00% ROIMDTMedtronic2/18/2026Lower Price Target$96.84$119.00Outperform$0.0000.00% ROITXG10x Genomics1/27/2026Lower Price Target$21.98$20.00Market Perform$0.0000.00% ROIPENPenumbra1/16/2026Downgrade$350.53Hold$0.0000.00% ROIPENPenumbra1/16/2026Reiterated Rating$350.53$374.00Market Perform$0.0000.00% ROIDXCMDexCom12/16/2025Reiterated Rating$65.73$92.00Outperform$0.0000.00% ROIMDTMedtronic11/19/2025Set Price Target$100.83$120.00Outperform$0.0000.00% ROINPCENeuroPace11/5/2025Reiterated Rating$9.40$19.00Outperform$0.0000.00% ROIPRCTPROCEPT BioRobotics11/5/2025Reiterated Rating$35.02$55.00Outperform$0.0000.00% ROIBSXBoston Scientific10/1/2025Boost Price Target$97.55$128.00Outperform$0.0000.00% ROIINSPInspire Medical Systems8/15/2025Lower Price Target$84.68$97.00Market Perform$0.0000.00% ROIBSXBoston Scientific6/16/2025Initiated Coverage$99.60$118.00Outperform$0.0000.00% ROIMDTMedtronic6/16/2025Initiated Coverage$87.19$110.00Outperform$0.0000.00% ROIBBNXBeta Bionics2/24/2025Initiated Coverage$20.57$28.00Outperform$00.0000.00% ROITXG10x Genomics2/13/2025Downgrade$12.00$12.00Market Perform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
